SlideShare a Scribd company logo
1 of 19
OUTPUT AND PRODUCTIVITY GROWTH IN THE
HEALTHCARE SECTOR:
A STUDY OF FOUR EUROPEAN COUNTRIES
Authors: Matilde Mas, Agnes Nagy, Mary O’Mahony
Erika Schulz and Lucy Stokes
Discussant: D.S. Prasada Rao
The main objectives are:
 To measure output and labour productivity in health sector
 To compare output and productivity growth
 in Germany, Hungary, Spain and the UK
 over the period 2004-2009
Objectives
 In the UK, total (NHS + private) expenditure on health
increased from £104.595 billion in 2004/05 to £ 151.700 billion
in 2011/12.
 Does this represent a 50% increase in the provision of health
services?
 What part of this is due to price increase?
 UK health expenditure statistics show that expenditure on
hospitals increased four-fold from £ 14.032 billion to £57,726.
 What is the increase in hospital output during the same period?
 Quality of hospital care would have changed over this period?
What can be said about quality adjusted output of hospitals?
 What are the implications for productivity growth?
 Are the levels and trends in output and productivity similar
in other countries in the region? This study focuses on
Germany, Hungary and Spain.
Motivation
 Measures of output of health sector
 The paper focuses on in- and out patient services
provided by hospitals
- Identify different types of outputs
- Aggregation of the outputs to derive a volume
measure
 Adjustment for quality change over time
 Identify suitable measures of quality
 Methodology to incorporate quality change into health
sector output
 Measures of inputs used in health sector
 Types of inputs (labour, capital, materials)
 Aggregation of inputs
 Focus of the paper is on labour productivity
Main Steps
Following the OECD handbook on measuring Education
and health output, output is measured using complete and
quality adjusted treatments.
A treatment is a “pathway that an individual takes through
heterogeneous institutions in the health industry in order to
receive full and final treatment for a disease or condition”
The focus of the paper is on treatments provided in
hospitals.
What exactly is the output of health sector?
 Inpatient care
 Treatment consisting of some procedure administered
to the patient or drug treatment that requires
monitoring of the patient in hospital
 Outpatient care
 Specialist consultations, pre-procedure and follow up
appointments
 Mental health services
 Community services
 Primary care
 Other activities – such as accident and emergency and
dialysis services
Types of health service
 The Diagnosis Related Groups (DRGs) are the main basis for
output measurement.
 Treatments are classified into different DRGs
 Classifications used in different countries may be
different
 Need to map the DRGs across countries and over time
to maintain comparability.
 The paper uses the number of episodes classified by DRGs as
the output measure.
 Need to derive a weighted output measure as different DRGs
involve different levels of input use and command different
prices in the case of marketed hospital services.
Output measurement
DRG Migrations - Germany
DRG 2008 DRG2009 DRG 2008 DRG2009
A07A A07A A09C A09C
A07A A07B A09C A09E
A07A A07C A09C A09F
A07A A07D A09C A09G
A07A A07E A09C B36A
A09C F36A
A09C G36Z
A09C R36Z
 In order to analyse trends in output and productivity in the sector, it is
necessary to aggregate outputs of different treatments.
 In the case of marketed activities, it is possible to use prices charged for
different treatments for aggregation.
 In the case of health sector, particularly in the case of hospitals, these
services are not always marketed.
 In some countries, patients pay nothing for the services they
receive.
 It is common practice to use unit costs to aggregate volumes of different
treatments.
 A Laspeyres index is used in the paper to measure output growth.
Output aggregation
11
1
1



  


, where output in ; unitcost
J
jt jtj
t t jt jtJ
jt jtj
x c
I x j t c t
x c
 The strategy here is to obtain a measure of quality of service provided:
 Waiting times
 Courtesy of health service staff
 Quality of food and cleanliness
 In-hospital mortality rates
 The measure used in the paper is:
Quality adjusted output index
1
11
*
, 1
1
where isthesurvivalratefor and
J jt
jt jtj
jt
t t jtJ
jt jtj
a
x c
a
I a j t
x c




 
  
 


 Focus of the paper is on labour productivity
 Labour is classified into difference categories, UK NHS
 Doctor and other medical staff
 Qualified nurses
 Qualified scientific, therapeutic & technical staff
 Qualified ambulance staff
 Support to clinical staff
 NHS infrastructure support
 Other non-medical staff
 Different countries have slightly different classifications
 Growth is measured by category and then weighted by the earnings share
or shared in the total salary costs in the sector
Input Growth
Hospital inpatient growth: Germany
-1
0
1
2
3
4
5
6
7
8
2004/05 2005/06 2006/07 2007/08
Activities
CWAI
CWOI
Hospital inpatient growth: UK
-1.00
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
2003/04 2004/05 2005/06 2006/07 2007/08 2008/09
Activities
CWAI
CWOI
Hospital inpatient growth: Spain
-1.00
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
2003/04 2004/05 2005/06 2006/07 2007/08 2008/09
Activities
CWAI
CWOI
Hospital inpatient growth: Hungary
-16.00
-14.00
-12.00
-10.00
-8.00
-6.00
-4.00
-2.00
0.00
2.00
4.00
6.00
2003/04 2004/05 2005/06 2006/07 2007/08 2008/09
Activities
CWAI
CWAI*
Growth in Output, Labour Input and Labour
Productivity, 2003-09
-4.00
-3.00
-2.00
-1.00
0.00
1.00
2.00
3.00
4.00
5.00
6.00
Germany Hungary Spain UK
output
Labour
Labour
productivity
Main findings
 In three of the four countries, similar labour productivity growth
was achieved through different channels
 significant output growth in Germany with no increase in labour input
 very high output growth in the UK but also relatively high growth in
labour input
 low output growth in Hungary accompanied by a significant reduction in
labour input
 Labour productivity growth in Spain significantly lags the other
countries
 Relatively high growth in labour input
Discussion
■ The paper represents a major empirical exercise spanning four countries
and the period 2004 to 2009.
■ Measurement issues had to be resolved
■ Changes to DRG specifications
■ Changes in accounting practices
■ Developing measures for non-hospital output
■ The paper also offers:
■ explanations for the results reported - big declines in output and
productivity in Hungary
■ results for difficult to compare activities of rehabilitation, mental
health and out-patient activities
■ The paper makes a significant contribution in shifting from an input-
based approach to an output-based approach to measure growth
Discussion
■ Index number formula: The paper makes use of the Laspeyres index to measure output
growth. Given that the paper reports year-on-year growth in output, it should be
feasible to compute Fisher or Tornqvist indices which are superlative.
■ Quality adjustment: Paper uses mortality rates as an indicator of quality.
■ This indicator would be relevant only for a small subset of DRGs covered in the
study.
■ A more relevant quality indicator would be the re-admission rates.
■ Sensitivity to the use of alternative quality indicators
■ Computation of quality adjusted output index
■ Use of cost shares as weights: As the authors point out use of cost shares is based on
technical and allocative efficiency of hospital operations
■ There are a number of studies measuring hospital inefficiency which means that use
of cost shares may not be appropriate
■ Are the results reported consistent with measures of performance of the health sector.
For example, are the output growth figures comparable to increases in “real
expenditure” in hospitals.
■ Finally, is it possible to use the OECD-Eurostat procedures developed for making cross
country comparisons in health and education sector? (e.g. paper by Koechlin, Konijn,
Lorenzoni and Schreyer to be discussed in Session 6A)

More Related Content

What's hot

Devising a New Approach for Projecting UK Medicines Expenditures
Devising a New Approach for Projecting UK Medicines ExpendituresDevising a New Approach for Projecting UK Medicines Expenditures
Devising a New Approach for Projecting UK Medicines ExpendituresOffice of Health Economics
 
Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice cheweb1
 
Country level cost saving with hospital inventory system.
Country level cost saving with hospital inventory system.Country level cost saving with hospital inventory system.
Country level cost saving with hospital inventory system.Mustafa Said YILDIZ
 
9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)Cittadinanzattiva onlus
 
Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Debbie Shields
 
Home Healthcare market
Home Healthcare market Home Healthcare market
Home Healthcare market danishsmith01
 
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013Office of Health Economics
 
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020Dietary supplements market in Poland 2015 Development forecasts for 2015-2020
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020Shrikant Mandlik
 
Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...Office of Health Economics
 
Maria Kouimtzi - MedicReS World Congress 2011
Maria Kouimtzi - MedicReS World Congress 2011Maria Kouimtzi - MedicReS World Congress 2011
Maria Kouimtzi - MedicReS World Congress 2011MedicReS
 
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardUsing MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardOffice of Health Economics
 
Μάκης Παπαταξιάρχης, 3rd Health Innovation Conference
Μάκης Παπαταξιάρχης, 3rd Health Innovation ConferenceΜάκης Παπαταξιάρχης, 3rd Health Innovation Conference
Μάκης Παπαταξιάρχης, 3rd Health Innovation ConferenceStarttech Ventures
 
Digital hospitals market report norway 20151222
Digital hospitals market report norway 20151222Digital hospitals market report norway 20151222
Digital hospitals market report norway 20151222Business Finland
 
Pharmaceutical Policies in Mexico: An International Perspective
Pharmaceutical Policies in Mexico: An International PerspectivePharmaceutical Policies in Mexico: An International Perspective
Pharmaceutical Policies in Mexico: An International PerspectiveOECD Governance
 
Supply Chain Management in healthcare
Supply Chain Management  in healthcareSupply Chain Management  in healthcare
Supply Chain Management in healthcareAnurag Gupta
 
Kh Forecasting Training Sp Kbm
Kh Forecasting Training   Sp KbmKh Forecasting Training   Sp Kbm
Kh Forecasting Training Sp KbmKARIMBENMAIZ
 
Spending reviews - Stefan Kiss, Slovak Republic
Spending reviews - Stefan Kiss, Slovak RepublicSpending reviews - Stefan Kiss, Slovak Republic
Spending reviews - Stefan Kiss, Slovak RepublicOECD Governance
 

What's hot (20)

Devising a New Approach for Projecting UK Medicines Expenditures
Devising a New Approach for Projecting UK Medicines ExpendituresDevising a New Approach for Projecting UK Medicines Expenditures
Devising a New Approach for Projecting UK Medicines Expenditures
 
Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice
 
Country level cost saving with hospital inventory system.
Country level cost saving with hospital inventory system.Country level cost saving with hospital inventory system.
Country level cost saving with hospital inventory system.
 
9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)
 
Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...Global regenerative medicines market (technology, application and geography) ...
Global regenerative medicines market (technology, application and geography) ...
 
Home Healthcare market
Home Healthcare market Home Healthcare market
Home Healthcare market
 
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
Projecting Medicines Expenditures in the English NHS Mestre-Ferrandiz AES 2013
 
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020Dietary supplements market in Poland 2015 Development forecasts for 2015-2020
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020
 
Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...Availability, accessibility and applicability of evidence: Transferability - ...
Availability, accessibility and applicability of evidence: Transferability - ...
 
Maria Kouimtzi - MedicReS World Congress 2011
Maria Kouimtzi - MedicReS World Congress 2011Maria Kouimtzi - MedicReS World Congress 2011
Maria Kouimtzi - MedicReS World Congress 2011
 
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways ForwardUsing MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
Using MCDA for HTA, Opportunities, Challenges and Possible Ways Forward
 
Μάκης Παπαταξιάρχης, 3rd Health Innovation Conference
Μάκης Παπαταξιάρχης, 3rd Health Innovation ConferenceΜάκης Παπαταξιάρχης, 3rd Health Innovation Conference
Μάκης Παπαταξιάρχης, 3rd Health Innovation Conference
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
 
Digital hospitals market report norway 20151222
Digital hospitals market report norway 20151222Digital hospitals market report norway 20151222
Digital hospitals market report norway 20151222
 
Pharmaceutical Policies in Mexico: An International Perspective
Pharmaceutical Policies in Mexico: An International PerspectivePharmaceutical Policies in Mexico: An International Perspective
Pharmaceutical Policies in Mexico: An International Perspective
 
Supply Chain Management in healthcare
Supply Chain Management  in healthcareSupply Chain Management  in healthcare
Supply Chain Management in healthcare
 
Health Technology Assessment (HTA): a tool for evidence-informed decision mak...
Health Technology Assessment (HTA): a tool for evidence-informed decision mak...Health Technology Assessment (HTA): a tool for evidence-informed decision mak...
Health Technology Assessment (HTA): a tool for evidence-informed decision mak...
 
Kh Forecasting Training Sp Kbm
Kh Forecasting Training   Sp KbmKh Forecasting Training   Sp Kbm
Kh Forecasting Training Sp Kbm
 
Spending reviews - Stefan Kiss, Slovak Republic
Spending reviews - Stefan Kiss, Slovak RepublicSpending reviews - Stefan Kiss, Slovak Republic
Spending reviews - Stefan Kiss, Slovak Republic
 
Health Technology Assessment : Interpreting a HTA report
Health Technology Assessment : Interpreting a HTA reportHealth Technology Assessment : Interpreting a HTA report
Health Technology Assessment : Interpreting a HTA report
 

Viewers also liked

Banka qendrore e europes
Banka qendrore e europesBanka qendrore e europes
Banka qendrore e europesshar bakalli
 
Puna ekipore si baze per lidership
Puna ekipore si baze per lidershipPuna ekipore si baze per lidership
Puna ekipore si baze per lidershipMenaxherat
 
Krizat ekonomike ligj.1
Krizat ekonomike ligj.1Krizat ekonomike ligj.1
Krizat ekonomike ligj.1Menaxherat
 
Sjellja organizative berim ramosaj
Sjellja organizative   berim ramosajSjellja organizative   berim ramosaj
Sjellja organizative berim ramosajMenaxherat
 
Nehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes Raiffeisen
Nehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes RaiffeisenNehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes Raiffeisen
Nehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes RaiffeisenTarget
 
26 Time Management Hacks I Wish I'd Known at 20
26 Time Management Hacks I Wish I'd Known at 2026 Time Management Hacks I Wish I'd Known at 20
26 Time Management Hacks I Wish I'd Known at 20Étienne Garbugli
 

Viewers also liked (7)

Banka qendrore e europes
Banka qendrore e europesBanka qendrore e europes
Banka qendrore e europes
 
Puna ekipore si baze per lidership
Puna ekipore si baze per lidershipPuna ekipore si baze per lidership
Puna ekipore si baze per lidership
 
Krizat ekonomike ligj.1
Krizat ekonomike ligj.1Krizat ekonomike ligj.1
Krizat ekonomike ligj.1
 
Sjellja organizative berim ramosaj
Sjellja organizative   berim ramosajSjellja organizative   berim ramosaj
Sjellja organizative berim ramosaj
 
Nehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes Raiffeisen
Nehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes RaiffeisenNehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes Raiffeisen
Nehar islami dhe Arben Dedaj-Krahasimi i bankes Teb dhe i bankes Raiffeisen
 
Lidershipi
LidershipiLidershipi
Lidershipi
 
26 Time Management Hacks I Wish I'd Known at 20
26 Time Management Hacks I Wish I'd Known at 2026 Time Management Hacks I Wish I'd Known at 20
26 Time Management Hacks I Wish I'd Known at 20
 

Similar to Session 2 a discussion of mary o'mahony paper in session 2a 25 august

Deloitte_ES_Sanidad-sanidad-en-europa.pdf
Deloitte_ES_Sanidad-sanidad-en-europa.pdfDeloitte_ES_Sanidad-sanidad-en-europa.pdf
Deloitte_ES_Sanidad-sanidad-en-europa.pdfjanethlopez72
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
DHL_LSH_Europe_Whitepaper_MedicalDevices_Web
DHL_LSH_Europe_Whitepaper_MedicalDevices_WebDHL_LSH_Europe_Whitepaper_MedicalDevices_Web
DHL_LSH_Europe_Whitepaper_MedicalDevices_WebIan Moore
 
Session 6 a iariw2014 session 6 a oecd eurostat
Session 6 a iariw2014 session 6 a oecd eurostatSession 6 a iariw2014 session 6 a oecd eurostat
Session 6 a iariw2014 session 6 a oecd eurostatIARIW 2014
 
Drug value optimization excerpts
Drug value optimization   excerptsDrug value optimization   excerpts
Drug value optimization excerptsJean-Michel Peny
 
mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.
mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.
mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.Levi Shapiro
 
DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)
DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)
DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)Paianet - Connecting Healthcare
 
Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019
Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019
Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019Massimo Talia
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACQuintilesIMS Asia Pacific
 
DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)
DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)
DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)Paianet - Connecting Healthcare
 
[Fsa] GSK fianacial statement analysis
[Fsa] GSK fianacial statement analysis[Fsa] GSK fianacial statement analysis
[Fsa] GSK fianacial statement analysisNguyen Thi Trang Nhung
 
2011June PharmaceuticalMarketEurope ValuableCollection
2011June PharmaceuticalMarketEurope ValuableCollection2011June PharmaceuticalMarketEurope ValuableCollection
2011June PharmaceuticalMarketEurope ValuableCollectionAleksandar Ruzicic
 
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
 
What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...
What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...
What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...OECD Governance
 

Similar to Session 2 a discussion of mary o'mahony paper in session 2a 25 august (20)

Deloitte_ES_Sanidad-sanidad-en-europa.pdf
Deloitte_ES_Sanidad-sanidad-en-europa.pdfDeloitte_ES_Sanidad-sanidad-en-europa.pdf
Deloitte_ES_Sanidad-sanidad-en-europa.pdf
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
DHL_LSH_Europe_Whitepaper_MedicalDevices_Web
DHL_LSH_Europe_Whitepaper_MedicalDevices_WebDHL_LSH_Europe_Whitepaper_MedicalDevices_Web
DHL_LSH_Europe_Whitepaper_MedicalDevices_Web
 
Session 6 a iariw2014 session 6 a oecd eurostat
Session 6 a iariw2014 session 6 a oecd eurostatSession 6 a iariw2014 session 6 a oecd eurostat
Session 6 a iariw2014 session 6 a oecd eurostat
 
Drug value optimization excerpts
Drug value optimization   excerptsDrug value optimization   excerpts
Drug value optimization excerpts
 
mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.
mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.
mHealth Israel_Guy Eiferman_Healthcare Services_Merck & Co.
 
DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)
DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)
DRG in Europe: Adaptation and trends- Wilm Quentin (Universität Berlin)
 
Jeremy Nurse
Jeremy NurseJeremy Nurse
Jeremy Nurse
 
Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019
Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019
Implementing-Value-Based-Healthcare-In-Europe-EIT-Summit-2019
 
The Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APACThe Impact Global Pharma Cost Containment Methods in APAC
The Impact Global Pharma Cost Containment Methods in APAC
 
DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)
DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)
DRG en Europe: Adaptations et tendances- Wilm Quentin (Universität Berlin)
 
[Fsa] GSK fianacial statement analysis
[Fsa] GSK fianacial statement analysis[Fsa] GSK fianacial statement analysis
[Fsa] GSK fianacial statement analysis
 
2011June PharmaceuticalMarketEurope ValuableCollection
2011June PharmaceuticalMarketEurope ValuableCollection2011June PharmaceuticalMarketEurope ValuableCollection
2011June PharmaceuticalMarketEurope ValuableCollection
 
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
 
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15
 
What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...
What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...
What are the challenges in measuring pulic sector efficiency? - Julian Kelly,...
 
ABPI big data road map
ABPI big data road mapABPI big data road map
ABPI big data road map
 
RDD 2020 Day 2 AM : Tania Stafinski
RDD 2020 Day 2 AM : Tania StafinskiRDD 2020 Day 2 AM : Tania Stafinski
RDD 2020 Day 2 AM : Tania Stafinski
 
Value-based healthcare in Spain
Value-based healthcare in SpainValue-based healthcare in Spain
Value-based healthcare in Spain
 
The debate on indication-based pricing
The debate on indication-based pricingThe debate on indication-based pricing
The debate on indication-based pricing
 

More from IARIW 2014

Session 7 d sakuma discussion
Session 7 d sakuma discussionSession 7 d sakuma discussion
Session 7 d sakuma discussionIARIW 2014
 
Session 7 d iariw 2014 session 7 d gueye and gruetz
Session 7 d iariw 2014 session 7 d gueye and gruetzSession 7 d iariw 2014 session 7 d gueye and gruetz
Session 7 d iariw 2014 session 7 d gueye and gruetzIARIW 2014
 
Session 7 d iariw 2014 session 7 d schmidt and heil
Session 7 d iariw 2014 session 7 d schmidt and heilSession 7 d iariw 2014 session 7 d schmidt and heil
Session 7 d iariw 2014 session 7 d schmidt and heilIARIW 2014
 
Session 7 d dutch revisioniariw
Session 7 d dutch revisioniariwSession 7 d dutch revisioniariw
Session 7 d dutch revisioniariwIARIW 2014
 
Session 7d van devenpresentation
Session 7d van devenpresentationSession 7d van devenpresentation
Session 7d van devenpresentationIARIW 2014
 
Session 7 c presentation session 7 c xuguang song & yafei wang
Session 7 c presentation session 7 c   xuguang song & yafei wangSession 7 c presentation session 7 c   xuguang song & yafei wang
Session 7 c presentation session 7 c xuguang song & yafei wangIARIW 2014
 
Session 7 c global corporate income
Session 7 c global corporate incomeSession 7 c global corporate income
Session 7 c global corporate incomeIARIW 2014
 
Session 7 a coli tartamella
Session 7 a coli tartamellaSession 7 a coli tartamella
Session 7 a coli tartamellaIARIW 2014
 
Session 7 a 20140829 rotterdam bruckmeier
Session 7 a 20140829 rotterdam bruckmeierSession 7 a 20140829 rotterdam bruckmeier
Session 7 a 20140829 rotterdam bruckmeierIARIW 2014
 
Session 7 a fantozzi raitano discussion_gv
Session 7 a fantozzi raitano discussion_gvSession 7 a fantozzi raitano discussion_gv
Session 7 a fantozzi raitano discussion_gvIARIW 2014
 
Session 7 a pabilonia paper presented by gao
Session 7 a pabilonia paper presented by gaoSession 7 a pabilonia paper presented by gao
Session 7 a pabilonia paper presented by gaoIARIW 2014
 
Session 7 b bobbio et al service lives paper 7 b iariw discussion
Session 7 b bobbio et al service lives paper 7 b iariw discussionSession 7 b bobbio et al service lives paper 7 b iariw discussion
Session 7 b bobbio et al service lives paper 7 b iariw discussionIARIW 2014
 
Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]
Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]
Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]IARIW 2014
 
Session 7 b 2014 08-29 voskob wu
Session 7 b 2014 08-29 voskob wuSession 7 b 2014 08-29 voskob wu
Session 7 b 2014 08-29 voskob wuIARIW 2014
 
Session 7 b 7 b role of capital in india’s economic growth
Session 7 b 7 b   role of capital in india’s economic growthSession 7 b 7 b   role of capital in india’s economic growth
Session 7 b 7 b role of capital in india’s economic growthIARIW 2014
 
Session 7 b iariw oulton 290814
Session 7 b iariw oulton 290814Session 7 b iariw oulton 290814
Session 7 b iariw oulton 290814IARIW 2014
 
Session 7 b d s rambaldi
Session 7 b d s rambaldiSession 7 b d s rambaldi
Session 7 b d s rambaldiIARIW 2014
 
Session 7 c de haan measuring global production in na_bp
Session 7 c de haan measuring global production in na_bpSession 7 c de haan measuring global production in na_bp
Session 7 c de haan measuring global production in na_bpIARIW 2014
 
Session 7 c iariw august14 erumban
Session 7 c iariw august14 erumbanSession 7 c iariw august14 erumban
Session 7 c iariw august14 erumbanIARIW 2014
 
Session 8 a iariw discussion clark paper -ruggles
Session 8 a iariw discussion clark paper -rugglesSession 8 a iariw discussion clark paper -ruggles
Session 8 a iariw discussion clark paper -rugglesIARIW 2014
 

More from IARIW 2014 (20)

Session 7 d sakuma discussion
Session 7 d sakuma discussionSession 7 d sakuma discussion
Session 7 d sakuma discussion
 
Session 7 d iariw 2014 session 7 d gueye and gruetz
Session 7 d iariw 2014 session 7 d gueye and gruetzSession 7 d iariw 2014 session 7 d gueye and gruetz
Session 7 d iariw 2014 session 7 d gueye and gruetz
 
Session 7 d iariw 2014 session 7 d schmidt and heil
Session 7 d iariw 2014 session 7 d schmidt and heilSession 7 d iariw 2014 session 7 d schmidt and heil
Session 7 d iariw 2014 session 7 d schmidt and heil
 
Session 7 d dutch revisioniariw
Session 7 d dutch revisioniariwSession 7 d dutch revisioniariw
Session 7 d dutch revisioniariw
 
Session 7d van devenpresentation
Session 7d van devenpresentationSession 7d van devenpresentation
Session 7d van devenpresentation
 
Session 7 c presentation session 7 c xuguang song & yafei wang
Session 7 c presentation session 7 c   xuguang song & yafei wangSession 7 c presentation session 7 c   xuguang song & yafei wang
Session 7 c presentation session 7 c xuguang song & yafei wang
 
Session 7 c global corporate income
Session 7 c global corporate incomeSession 7 c global corporate income
Session 7 c global corporate income
 
Session 7 a coli tartamella
Session 7 a coli tartamellaSession 7 a coli tartamella
Session 7 a coli tartamella
 
Session 7 a 20140829 rotterdam bruckmeier
Session 7 a 20140829 rotterdam bruckmeierSession 7 a 20140829 rotterdam bruckmeier
Session 7 a 20140829 rotterdam bruckmeier
 
Session 7 a fantozzi raitano discussion_gv
Session 7 a fantozzi raitano discussion_gvSession 7 a fantozzi raitano discussion_gv
Session 7 a fantozzi raitano discussion_gv
 
Session 7 a pabilonia paper presented by gao
Session 7 a pabilonia paper presented by gaoSession 7 a pabilonia paper presented by gao
Session 7 a pabilonia paper presented by gao
 
Session 7 b bobbio et al service lives paper 7 b iariw discussion
Session 7 b bobbio et al service lives paper 7 b iariw discussionSession 7 b bobbio et al service lives paper 7 b iariw discussion
Session 7 b bobbio et al service lives paper 7 b iariw discussion
 
Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]
Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]
Session 7 b commentson daneilkerpaperonukr&d servicelives2014iariw[1]
 
Session 7 b 2014 08-29 voskob wu
Session 7 b 2014 08-29 voskob wuSession 7 b 2014 08-29 voskob wu
Session 7 b 2014 08-29 voskob wu
 
Session 7 b 7 b role of capital in india’s economic growth
Session 7 b 7 b   role of capital in india’s economic growthSession 7 b 7 b   role of capital in india’s economic growth
Session 7 b 7 b role of capital in india’s economic growth
 
Session 7 b iariw oulton 290814
Session 7 b iariw oulton 290814Session 7 b iariw oulton 290814
Session 7 b iariw oulton 290814
 
Session 7 b d s rambaldi
Session 7 b d s rambaldiSession 7 b d s rambaldi
Session 7 b d s rambaldi
 
Session 7 c de haan measuring global production in na_bp
Session 7 c de haan measuring global production in na_bpSession 7 c de haan measuring global production in na_bp
Session 7 c de haan measuring global production in na_bp
 
Session 7 c iariw august14 erumban
Session 7 c iariw august14 erumbanSession 7 c iariw august14 erumban
Session 7 c iariw august14 erumban
 
Session 8 a iariw discussion clark paper -ruggles
Session 8 a iariw discussion clark paper -rugglesSession 8 a iariw discussion clark paper -ruggles
Session 8 a iariw discussion clark paper -ruggles
 

Session 2 a discussion of mary o'mahony paper in session 2a 25 august

  • 1. OUTPUT AND PRODUCTIVITY GROWTH IN THE HEALTHCARE SECTOR: A STUDY OF FOUR EUROPEAN COUNTRIES Authors: Matilde Mas, Agnes Nagy, Mary O’Mahony Erika Schulz and Lucy Stokes Discussant: D.S. Prasada Rao
  • 2. The main objectives are:  To measure output and labour productivity in health sector  To compare output and productivity growth  in Germany, Hungary, Spain and the UK  over the period 2004-2009 Objectives
  • 3.  In the UK, total (NHS + private) expenditure on health increased from £104.595 billion in 2004/05 to £ 151.700 billion in 2011/12.  Does this represent a 50% increase in the provision of health services?  What part of this is due to price increase?  UK health expenditure statistics show that expenditure on hospitals increased four-fold from £ 14.032 billion to £57,726.  What is the increase in hospital output during the same period?  Quality of hospital care would have changed over this period? What can be said about quality adjusted output of hospitals?  What are the implications for productivity growth?  Are the levels and trends in output and productivity similar in other countries in the region? This study focuses on Germany, Hungary and Spain. Motivation
  • 4.  Measures of output of health sector  The paper focuses on in- and out patient services provided by hospitals - Identify different types of outputs - Aggregation of the outputs to derive a volume measure  Adjustment for quality change over time  Identify suitable measures of quality  Methodology to incorporate quality change into health sector output  Measures of inputs used in health sector  Types of inputs (labour, capital, materials)  Aggregation of inputs  Focus of the paper is on labour productivity Main Steps
  • 5. Following the OECD handbook on measuring Education and health output, output is measured using complete and quality adjusted treatments. A treatment is a “pathway that an individual takes through heterogeneous institutions in the health industry in order to receive full and final treatment for a disease or condition” The focus of the paper is on treatments provided in hospitals. What exactly is the output of health sector?
  • 6.  Inpatient care  Treatment consisting of some procedure administered to the patient or drug treatment that requires monitoring of the patient in hospital  Outpatient care  Specialist consultations, pre-procedure and follow up appointments  Mental health services  Community services  Primary care  Other activities – such as accident and emergency and dialysis services Types of health service
  • 7.  The Diagnosis Related Groups (DRGs) are the main basis for output measurement.  Treatments are classified into different DRGs  Classifications used in different countries may be different  Need to map the DRGs across countries and over time to maintain comparability.  The paper uses the number of episodes classified by DRGs as the output measure.  Need to derive a weighted output measure as different DRGs involve different levels of input use and command different prices in the case of marketed hospital services. Output measurement
  • 8. DRG Migrations - Germany DRG 2008 DRG2009 DRG 2008 DRG2009 A07A A07A A09C A09C A07A A07B A09C A09E A07A A07C A09C A09F A07A A07D A09C A09G A07A A07E A09C B36A A09C F36A A09C G36Z A09C R36Z
  • 9.  In order to analyse trends in output and productivity in the sector, it is necessary to aggregate outputs of different treatments.  In the case of marketed activities, it is possible to use prices charged for different treatments for aggregation.  In the case of health sector, particularly in the case of hospitals, these services are not always marketed.  In some countries, patients pay nothing for the services they receive.  It is common practice to use unit costs to aggregate volumes of different treatments.  A Laspeyres index is used in the paper to measure output growth. Output aggregation 11 1 1         , where output in ; unitcost J jt jtj t t jt jtJ jt jtj x c I x j t c t x c
  • 10.  The strategy here is to obtain a measure of quality of service provided:  Waiting times  Courtesy of health service staff  Quality of food and cleanliness  In-hospital mortality rates  The measure used in the paper is: Quality adjusted output index 1 11 * , 1 1 where isthesurvivalratefor and J jt jt jtj jt t t jtJ jt jtj a x c a I a j t x c             
  • 11.  Focus of the paper is on labour productivity  Labour is classified into difference categories, UK NHS  Doctor and other medical staff  Qualified nurses  Qualified scientific, therapeutic & technical staff  Qualified ambulance staff  Support to clinical staff  NHS infrastructure support  Other non-medical staff  Different countries have slightly different classifications  Growth is measured by category and then weighted by the earnings share or shared in the total salary costs in the sector Input Growth
  • 12. Hospital inpatient growth: Germany -1 0 1 2 3 4 5 6 7 8 2004/05 2005/06 2006/07 2007/08 Activities CWAI CWOI
  • 13. Hospital inpatient growth: UK -1.00 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 Activities CWAI CWOI
  • 14. Hospital inpatient growth: Spain -1.00 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 Activities CWAI CWOI
  • 15. Hospital inpatient growth: Hungary -16.00 -14.00 -12.00 -10.00 -8.00 -6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 Activities CWAI CWAI*
  • 16. Growth in Output, Labour Input and Labour Productivity, 2003-09 -4.00 -3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 4.00 5.00 6.00 Germany Hungary Spain UK output Labour Labour productivity
  • 17. Main findings  In three of the four countries, similar labour productivity growth was achieved through different channels  significant output growth in Germany with no increase in labour input  very high output growth in the UK but also relatively high growth in labour input  low output growth in Hungary accompanied by a significant reduction in labour input  Labour productivity growth in Spain significantly lags the other countries  Relatively high growth in labour input
  • 18. Discussion ■ The paper represents a major empirical exercise spanning four countries and the period 2004 to 2009. ■ Measurement issues had to be resolved ■ Changes to DRG specifications ■ Changes in accounting practices ■ Developing measures for non-hospital output ■ The paper also offers: ■ explanations for the results reported - big declines in output and productivity in Hungary ■ results for difficult to compare activities of rehabilitation, mental health and out-patient activities ■ The paper makes a significant contribution in shifting from an input- based approach to an output-based approach to measure growth
  • 19. Discussion ■ Index number formula: The paper makes use of the Laspeyres index to measure output growth. Given that the paper reports year-on-year growth in output, it should be feasible to compute Fisher or Tornqvist indices which are superlative. ■ Quality adjustment: Paper uses mortality rates as an indicator of quality. ■ This indicator would be relevant only for a small subset of DRGs covered in the study. ■ A more relevant quality indicator would be the re-admission rates. ■ Sensitivity to the use of alternative quality indicators ■ Computation of quality adjusted output index ■ Use of cost shares as weights: As the authors point out use of cost shares is based on technical and allocative efficiency of hospital operations ■ There are a number of studies measuring hospital inefficiency which means that use of cost shares may not be appropriate ■ Are the results reported consistent with measures of performance of the health sector. For example, are the output growth figures comparable to increases in “real expenditure” in hospitals. ■ Finally, is it possible to use the OECD-Eurostat procedures developed for making cross country comparisons in health and education sector? (e.g. paper by Koechlin, Konijn, Lorenzoni and Schreyer to be discussed in Session 6A)

Editor's Notes

  1. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  2. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  3. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  4. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  5. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  6. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  7. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  8. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  9. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  10. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).
  11. The geometric lag has the advantage of being relatively simple. But there are many instances where it is unreasonable to assume that the first lag weight is the largest (e.g., the inflation example).